These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 26028995)
21. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer. Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800 [TBL] [Abstract][Full Text] [Related]
22. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Bhattu AS; Zappala SM; Parekh DJ; Punnen S Urology; 2021 Feb; 148():53-58. PubMed ID: 33217456 [TBL] [Abstract][Full Text] [Related]
23. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. McDonald ML; Parsons JK Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027 [TBL] [Abstract][Full Text] [Related]
24. Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI. Marzouk K; Ehdaie B; Vertosick E; Zappala S; Vickers A Urol Oncol; 2019 Oct; 37(10):672-677. PubMed ID: 31378585 [TBL] [Abstract][Full Text] [Related]
25. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228 [TBL] [Abstract][Full Text] [Related]
26. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. Haese A; Dworschack RT; Partin AW J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298 [TBL] [Abstract][Full Text] [Related]
27. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815 [TBL] [Abstract][Full Text] [Related]
28. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162 [TBL] [Abstract][Full Text] [Related]
29. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
30. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449 [TBL] [Abstract][Full Text] [Related]
31. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7. Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847 [TBL] [Abstract][Full Text] [Related]
32. A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. Haese A; Tin AL; Carlsson SV; Sjoberg DD; Pehrke D; Steuber T; Huland H; Graefen M; Scardino PT; Schlomm T; Vickers AJ; Lilja H; Sauter G Br J Cancer; 2020 Aug; 123(4):604-609. PubMed ID: 32467601 [TBL] [Abstract][Full Text] [Related]
33. Novel Biomarkers for Prostate Cancer Detection and Prognosis. Filella X; Foj L Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547 [TBL] [Abstract][Full Text] [Related]
34. Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. Hougen HY; Reis IM; Han S; Prakash NS; Thomas J; Stoyanova R; Castillo RP; Kryvenko ON; Ritch CR; Nahar B; Gonzalgo ML; Gaston SM; Abramowitz MC; Dal Pra A; Mahal BA; Pollack A; Parekh DJ; Punnen S Prostate Cancer Prostatic Dis; 2024 Sep; ():. PubMed ID: 39333697 [TBL] [Abstract][Full Text] [Related]
35. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*. Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865 [TBL] [Abstract][Full Text] [Related]
37. Blood-based biomarkers of aggressive prostate cancer. Liong ML; Lim CR; Yang H; Chao S; Bong CW; Leong WS; Das PK; Loh CS; Lau BE; Yu CG; Ooi EJ; Nam RK; Allen PD; Steele GS; Wassmann K; Richie JP; Liew CC PLoS One; 2012; 7(9):e45802. PubMed ID: 23071848 [TBL] [Abstract][Full Text] [Related]
38. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.]. Murray NP; Fuentealba C; Reyes E; Jacob O Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202 [TBL] [Abstract][Full Text] [Related]
39. Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples. Higgins CE; Neybold P; Holdridge MB; Barnes CR; Dong Y; Reeve M; Mathur V; Weisberger J; Linder V J Appl Lab Med; 2018 Sep; 3(2):185-199. PubMed ID: 33636931 [TBL] [Abstract][Full Text] [Related]
40. The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. Darst BF; Chou A; Wan P; Pooler L; Sheng X; Vertosick EA; Conti DV; Wilkens LR; Le Marchand L; Vickers AJ; Lilja HG; Haiman CA Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1381-1388. PubMed ID: 32385116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]